Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

Ico Therapeutics completes Phase 2 iDEAL study for treatment of diabetic macular edema

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

pSivida reports that NICE issues draft guidance for use of ILUVIEN for pseudophakic patients with DME

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

NICE Appraisal Committee reconfirms clinical effectiveness of ILUVIEN

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

Alimera announces availability of ILUVIEN in U.K. for chronic DME treatment

pSivida announces resubmission of ILUVIEN NDA to FDA for chronic diabetic macular edema

pSivida announces resubmission of ILUVIEN NDA to FDA for chronic diabetic macular edema

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

Subclinical inflammation predicts macular disease

Subclinical inflammation predicts macular disease

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals starts Optina clinical trial

Regeneron fourth quarter total revenues increase to $415 million

Regeneron fourth quarter total revenues increase to $415 million

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

Bayer submits MAA in Europe for EYLEA to treat macular edema after CRVO

NICE reject intravitreal implant for diabetic macular edema

NICE reject intravitreal implant for diabetic macular edema

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

EC approves Regeneron’s EYLEA for treatment of wet AMD

EC approves Regeneron’s EYLEA for treatment of wet AMD

Ranibizumab improves driving prospects for AMD patients

Ranibizumab improves driving prospects for AMD patients

Ranibizumab injections keep those with AMD driving longer

Ranibizumab injections keep those with AMD driving longer

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema